US · ZTS
Zoetis Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Parsippany, NJ 07054
- Website
- zoetis.com
Price · as of 2025-12-31
$114.16
Market cap 57.77B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $121.99 | +6.86% |
| Intrinsic Value(DCF) | $78.89 | -30.9% |
| Graham-Dodd Method(GD) | $1.34 | -98.83% |
| Graham Formula(GF) | $61.69 | -45.96% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $13.09 | |||
| 2012 | $30.69 | $39.10 | $3.60 | $8.55 | $9.09 |
| 2013 | $27.77 | $39.19 | $1.83 | $2.02 | $13.21 |
| 2014 | $42.53 | $45.43 | $2.55 | $2.12 | $15.03 |
| 2015 | $38.63 | $40.89 | $5.30 | $0.00 | $5.26 |
| 2016 | $49.61 | $49.08 | $4.78 | $2.60 | $17.58 |
| 2017 | $79.16 | $66.18 | $0.00 | $3.04 | $28.85 |
| 2018 | $87.09 | $73.07 | $0.18 | $6.54 | $51.74 |
| 2019 | $129.91 | $88.37 | $5.92 | $6.08 | $47.71 |
| 2020 | $145.47 | $99.81 | $19.04 | $7.50 | $49.76 |
| 2021 | $177.65 | $124.18 | $41.44 | $10.41 | $102.28 |
| 2022 | $156.12 | $107.36 | $46.23 | $6.54 | $53.91 |
| 2023 | $177.65 | $126.96 | $38.73 | $7.76 | $69.52 |
| 2024 | $167.93 | $122.40 | $50.25 | $5.91 | $88.48 |
| 2025 | $128.96 | $121.99 | $48.52 | $1.34 | $61.69 |
AI valuation
Our deep-learning model estimates Zoetis Inc.'s (ZTS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $121.99
- Current price
- $114.16
- AI upside
- +6.86%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$78.89
-30.9% upside
Graham-Dodd
$1.34
-98.83% upside
Graham Formula
$61.69
-45.96% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ZTS | Zoetis Inc. | $114.16 | 57.77B | +7% | -31% | -99% | -46% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CI | Cigna Corporation | $289.82 | 77.42B | -21% | +327% | -97% | +46% | 12.30 | 1.85 | 0.28 | 8.71 | 14.84 | -2.43 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 8292.00% | 1126.00% | -634.00% | 10.85% | 0.17 | 12.88% | 2.08% | 25.60% | 7.58% | 11.08 | 12.06 | 0.37 | 2.69 |
| COR | Cencora, Inc. | $372.14 | 72.39B | -33% | -64% | — | -63% | 41.92 | 43.58 | 0.20 | 19.29 | 734.06 | -4.12 | 3.16% | 1.14% | 0.48% | 145.58% | 42.46% | 2.18% | 7.13 | 8.69 | 0.90 | 0.51 | 1.70 | 571.00% | 931.00% | 699.00% | 4.88% | 0.07 | 53.77% | 0.67% | 27.90% | 1.33% | 19.76 | 22.47 | 0.22 | 4.91 |
| ELAN | Elanco Animal Health Inco… | $26.40 | 13.12B | +23% | -60% | -95% | — | -55.82 | 1.98 | 2.75 | 24.29 | — | -7.90 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -16912.00% | 622.00% | -2792.00% | 2.19% | 0.35 | 2.84% | 0.00% | 0.00% | 2.94% | 65.17 | 57.83 | 3.48 | 1.49 |
| ELV | Elevance Health Inc. | $320.00 | 70.63B | -31% | -45% | -71% | +61% | 11.52 | 1.49 | 0.33 | 9.21 | — | 15.04 | 25.56% | 4.07% | 2.84% | 13.29% | 10.26% | 4.75% | 0.76 | 5.79 | 1.24 | 1.24 | 2.46 | -218.00% | 1262.00% | -3027.00% | 4.87% | 0.21 | 4.76% | 2.34% | 27.00% | 7.36% | 10.97 | 28.03 | 0.45 | 2.82 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| IDXX | IDEXX Laboratories, Inc. | $656.73 | 52.44B | -34% | -40% | -88% | -64% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| REGN | Regeneron Pharmaceuticals… | $781.67 | 81.22B | -37% | -58% | -41% | -50% | 18.36 | 2.65 | 5.77 | 13.20 | 224.20 | 2.76 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 819.00% | 99.00% | 1135.00% | 4.93% | 1.14 | 16.86% | 0.45% | 8.20% | 5.36% | 21.47 | 18.83 | 5.36 | 7.62 |
| TAK | Takeda Pharmaceutical Com… | $18.75 | 59.23B | +21% | -68% | — | -82% | 66.53 | 1.04 | 1.57 | 9.33 | — | -3.55 | 65.51% | 7.48% | 2.36% | 1.52% | 1.87% | 0.74% | 0.65 | 2.49 | 1.01 | 0.45 | 3.41 | -2624.00% | 745.00% | 26347.00% | 11.93% | 0.42 | 7.55% | 4.21% | 280.30% | 8.50% | 32.96 | 13.18 | 2.46 | 1.11 |
About Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
- CEO
- Kristin C. Peck
- Employees
- 13.8K
- Beta
- 0.96
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($78.89 ÷ $114.16) − 1 = -30.9% (DCF, example).